106577-99-5

Basic information

• Product Name: 6-Chloro-3-(2-broMoacetyl)-2-chroMenone
• Synonyms: 6-Chloro-3-(2-broMoacetyl)-2-chroMenone;3-(2-bromoacetyl)-6-chloro-2H-1-benzopyran-2-one
• CAS NO: 106577-99-5
• Molecular Formula: C₁₁H₆BrClO₃
• Molecular Weight: 301.52054
• Mol File: 106577-99-5.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Chloro-3-(2-broMoacetyl)-2-chroMenone(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-3-(2-broMoacetyl)-2-chroMenone(106577-99-5)
• EPA Substance Registry System: 6-Chloro-3-(2-broMoacetyl)-2-chroMenone(106577-99-5)

Safety Data

• Hazardous Substances Data: 106577-99-5(Hazardous Substances Data)

Usage

General Description

6-Chloro-3-(2-bromoacetyl)-2-chromenone is a chemical compound with the molecular formula C11H8O3ClBr. It is a derivative of 2-chromenone, a type of flavonoid found in certain plants. 6-Chloro-3-(2-broMoacetyl)-2-chroMenone is known for its potential antibacterial and antifungal properties, making it a possible candidate for use in pharmaceuticals and agricultural applications. Its structure contains a chloro and bromo functional group, which can potentially contribute to its biological activity. Further research and testing are needed to fully understand the potential uses and effects of 6-Chloro-3-(2-bromoacetyl)-2-chromenone.

Upstream product

• 53653-66-0 3-acetyl-6-chlorocoumarin 
• 2420-26-0 4-chlorosalicylaldehyde 
• 635-93-8 5-chlorosalicyclaldehyde 

Downstream Products

• 106578-09-0 6-Chloro-3-(2-phenyl-thiazol-4-yl)-chromen-2-one 
• 228854-68-0 propionic acid N'-[4-(6-chloro-2-oxo-2H-chromen-3-yl)-thiazol-2-yl]-hydrazide 
• 430455-85-9 3-(6-chloro-2-oxo-2H-chromen-3-yl)-[1,3,4]thiadiazino[2,3-b]quinazolin-6(2H)-one 
• 896381-18-3 6-chloro-3-(2-(phenylsulfonyl)acetyl)-2H-chromen-2-one 
• 896381-24-1 6-chloro-3-[2-(4-methylphenylsulfonyl)acetyl]-2H-chromen-2-one 

Relevant articles and documents

Synthesis of Some 2-(3-Alkyl/aryl-5-trifluoromethylpyrazol-1-yl)-4-(coumarin-3-yl)thiazoles as novel antibacterial agents

Herein, we describe a one-pot synthesis of some novel 2-(3-alkyl/aryl-5-trifluoromethylpyrazol-1-yl)-4-(coumarin-3-yl)thiazoles (6) involving the reaction of 3-alkyl/aryl-5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazole-1-thiocarboxamides (3) with 3-bromoacetylcoumarins (5) in the presence of sodium carbonate in ethanol. Reaction of 3 with 5 in the absence of sodium carbonate, however, resulted in the formation of 2-(3-alkyl/aryl-5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles, which were subsequently dehydrated to 6 by refluxing in ethanol in the presence of sodium carbonate. The structure of the synthesized compounds (6) was confirmed by infrared (IR), mass, 1H NMR, and 13C NMR spectra and elemental analysis data. Newly synthesized compounds (6) showed moderate to good activity against Gram-positive bacteria.

Synthesis and antimicrobial activity of some novel quinoline-pyrazoline-based coumarinyl thiazole derivatives

A series of novel 3-(2-(5-(2-chloroquinolin-3-yl)-3-substituted phenyl-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4-yl)-6-H/halo-2H-chromen-2-ones (9a–9y) was prepared as antimicrobial agents by the condensation of 3-(2-bromoacetyl)-6-H/halo-2H-chromen-2-ones (4

Design, synthesis, DFT, docking studies and ADME prediction of some new coumarinyl linked pyrazolylthiazoles: Potential standalone or adjuvant antimicrobial agents

The control of antimicrobial resistance (AMR) seems to have come to a dead end. The major consequences of the use and abuse of antibacterial drugs are the development of resistant strains due to genetic mutability of both pathogenic and nonpathogenic microorganisms. We, herein, report the synthesis, characterization and biological activities of coumarin-thiazole-pyrazole (CTP) molecular hybrids with an effort to explore and overcome the increasing antimicrobial resistance. The compounds were characterized by analyzing their IR, Mass, 1H and13C NMR spectral data and elemental analysis. The in vitro antimicrobial activity of the synthesized compounds was investigated against various pathogenic strains; the results obtained were further explained with the help of DFT and molecular orbital calculations. Compound 1b and 1f displayed good antimicrobial activity and synergistic effects when used with kanamycin and amphotericin B. Furthermore, in vitro cytotoxicity of compounds 1b and 1f were studied against HeLa cells (cervical cancer cell) and Hek-293 cells. The results of molecular docking study were used to better rationalize the action and prediction of the binding modes of these compounds.